K. Govind Babu

605 total citations
31 papers, 272 citations indexed

About

K. Govind Babu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, K. Govind Babu has authored 31 papers receiving a total of 272 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 9 papers in Otorhinolaryngology. Recurrent topics in K. Govind Babu's work include Head and Neck Cancer Studies (9 papers), Lymphoma Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). K. Govind Babu is often cited by papers focused on Head and Neck Cancer Studies (9 papers), Lymphoma Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). K. Govind Babu collaborates with scholars based in India, United States and United Kingdom. K. Govind Babu's co-authors include KC Lakshmaiah, M. S. Vidyasagar, Balaswamy Reddy, P.P. Bapsy, L K Rajeev, Linu Abraham Jacob, Lokanatha Dasappa, Philipp D. le Coutre, Jörge E. Cortes and José López and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

K. Govind Babu

27 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Govind Babu India 9 142 99 82 64 47 31 272
P.P. Bapsy India 8 183 1.3× 131 1.3× 151 1.8× 56 0.9× 38 0.8× 31 341
Jan‐Olof Fernberg Sweden 9 107 0.8× 60 0.6× 179 2.2× 99 1.5× 29 0.6× 11 309
Marcus Couey United States 6 293 2.1× 87 0.9× 98 1.2× 98 1.5× 17 0.4× 16 375
L K Rajeev India 9 117 0.8× 18 0.2× 59 0.7× 43 0.7× 29 0.6× 63 224
Fuat Demirelli Türkiye 11 135 1.0× 18 0.2× 97 1.2× 58 0.9× 20 0.4× 34 296
Vasu Divi United States 9 141 1.0× 223 2.3× 66 0.8× 214 3.3× 33 0.7× 15 356
Federico Sackmann‐Muriel Argentina 13 98 0.7× 58 0.6× 48 0.6× 54 0.8× 75 1.6× 25 396
Xiaofei Sun China 10 79 0.6× 25 0.3× 81 1.0× 48 0.8× 9 0.2× 68 262
P. Castellucci Italy 5 220 1.5× 34 0.3× 51 0.6× 56 0.9× 35 0.7× 10 367
M. Tao Singapore 4 130 0.9× 89 0.9× 92 1.1× 52 0.8× 57 1.2× 19 358

Countries citing papers authored by K. Govind Babu

Since Specialization
Citations

This map shows the geographic impact of K. Govind Babu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Govind Babu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Govind Babu more than expected).

Fields of papers citing papers by K. Govind Babu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Govind Babu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Govind Babu. The network helps show where K. Govind Babu may publish in the future.

Co-authorship network of co-authors of K. Govind Babu

This figure shows the co-authorship network connecting the top 25 collaborators of K. Govind Babu. A scholar is included among the top collaborators of K. Govind Babu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Govind Babu. K. Govind Babu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kim, Dongwook, Ullas Batra, K. Park, et al.. (2020). 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial. Annals of Oncology. 31. S864–S865. 1 indexed citations
3.
Parikh, Purvish M., et al.. (2020). “Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic. Indian Journal of Medical and Paediatric Oncology. 41(2). 127–131. 2 indexed citations
4.
Lakshmaiah, KC, et al.. (2018). Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a nonendemic region. Indian Journal of Cancer. 55(3). 257–257. 5 indexed citations
5.
Babu, K. Govind, et al.. (2018). Correlation of BMI with breast cancer subtype and tumour size. ecancermedicalscience. 12. 845–845. 13 indexed citations
6.
Lakshmaiah, KC, et al.. (2017). Induction chemotherapy in technically unresectable locally advanced T4a oral cavity squamous cell cancers: Experience from a regional cancer center of South India. Indian Journal of Medical and Paediatric Oncology. 38(4). 490–490. 15 indexed citations
7.
Lakshmaiah, KC, et al.. (2017). Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: Experience at a regional cancer centre in India. South Asian Journal of Cancer. 6(2). 69–71. 12 indexed citations
8.
Lakshmaiah, K C, et al.. (2017). Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: A regional cancer center experience. Indian Journal of Cancer. 54(1). 35–38. 10 indexed citations
9.
10.
Cortes, Jörge E., Cármino Antônio De Souza, Manuel Ayala, et al.. (2016). Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. The Lancet Haematology. 3(12). e581–e591. 26 indexed citations
11.
Lakshmaiah, KC, et al.. (2016). Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study. Lung India. 33(2). 154–154. 3 indexed citations
12.
Babu, K. Govind, et al.. (2015). Linezolid induced vasculitis: An unusual case report with review of the literature. SHILAP Revista de lepidopterología. 42(1). 27–27. 2 indexed citations
13.
14.
Ganguly, Sandip, et al.. (2014). Burkitt lymphoma of bone: A single institutional experience. 3(3). 23–23. 1 indexed citations
15.
Babu, K. Govind, et al.. (2014). Primary central nervous system lymphoma: An Indian Perspective. Clinical Cancer Investigation Journal. 3(6). 514–514. 2 indexed citations
16.
17.
Lakshmaiah, KC, et al.. (2014). Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. Annals of Saudi Medicine. 34(6). 551–554. 4 indexed citations
18.
Cortes, Jörge E., Cármino Antônio De Souza, José López, et al.. (2013). Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial. Blood. 122(21). 95–95. 7 indexed citations
19.
20.
Babu, K. Govind, et al.. (2007). Impact of diabetes on cancer chemotherapy outcome: A retrospective analysis. International Journal of Diabetes in Developing Countries. 27(4). 122–122. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P.P. Bapsy Breakdown of academic impact, for papers by Jan‐Olof Fernberg Breakdown of academic impact, for papers by Marcus Couey Breakdown of academic impact, for papers by L K Rajeev Breakdown of academic impact, for papers by Fuat Demirelli Breakdown of academic impact, for papers by Vasu Divi Breakdown of academic impact, for papers by Federico Sackmann‐Muriel Breakdown of academic impact, for papers by Xiaofei Sun Breakdown of academic impact, for papers by P. Castellucci Breakdown of academic impact, for papers by M. Tao
Rankless by CCL
2026